Insider Selling: Seer, Inc. (NASDAQ:SEER) CEO Sells $18,072.32 in Stock

Seer, Inc. (NASDAQ:SEER) CEO Omid Farokhzad sold 8,068 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $2.24, for a total transaction of $18,072.32. Following the completion of the sale, the chief executive officer now directly owns 1,428,217 shares in the company, valued at $3,199,206.08. This trade represents a 0.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Seer Stock Down 3.0 %

SEER opened at $2.26 on Friday. Seer, Inc. has a one year low of $1.51 and a one year high of $2.63. The stock’s 50 day moving average price is $2.36 and its 200-day moving average price is $2.07.

Hedge Funds Weigh In On Seer

Several hedge funds have recently bought and sold shares of the business. Barclays PLC boosted its stake in shares of Seer by 34.1% during the third quarter. Barclays PLC now owns 64,426 shares of the company’s stock valued at $127,000 after purchasing an additional 16,382 shares during the period. XTX Topco Ltd purchased a new stake in Seer in the 3rd quarter valued at about $123,000. Geode Capital Management LLC grew its stake in Seer by 5.9% in the 3rd quarter. Geode Capital Management LLC now owns 446,329 shares of the company’s stock worth $879,000 after acquiring an additional 25,002 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Seer by 67.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 175,354 shares of the company’s stock worth $345,000 after acquiring an additional 70,671 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Seer during the second quarter worth approximately $133,000. Institutional investors own 75.20% of the company’s stock.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.